lutetium-177 psma-i&t,radium-223
novartis,bayer
['crpc', 'alphabet', 'tps280', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bayer']
#ascogu: alphabet is a phase 1/2 trial in progress in patients with #mcrpc. #gu23: abstract tps280, trials in progress poster session a.
Driving innovation in cancer care for patients.

By following this account you confirm that you are an HCP & accept our community guidelines: https://t.co/iYZUrNHHuk